相关实验视频

Updated: Jul 6, 2025

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

在接受新辅助化疗的乳腺癌中,HER2低表达演变的临床病理学特征和值

Yingbo Shao¹, Huijuan Guan², Zhifen Luo³

¹Department of Breast Oncology, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Zhengzhou, Henan, 450003, China; Department of Breast Oncology, Henan Provincial People's Hospital, Henan University People's Hospital, Zhengzhou, Henan, 450003, China.

Breast (Edinburgh, Scotland)

|December 30, 2023

概括

与HER2-zero相比,HER2-low乳腺癌表现出不同的特征和治疗反应. 在新辅助化疗 (NAC) 后的HER2表达演变因亚型而异,但不会影响预后.

科学领域:

在瘤学瘤学.
乳腺癌研究研究乳腺癌研究
分子诊断学分子诊断学

背景情况:

人们越来越多地认识到低HER2的乳腺癌,因此需要对其特征有更深入的了解.
新辅助化疗 (NAC) 是许多乳腺癌的标准治疗方法.
在NAC之后HER2表达的演变并没有得到很好的描述,特别是在HER2-低和HER2-零种群中.

研究的目的:

为了评估HER2-低乳腺癌的临床病理特征.
评估对HER2-低与HER2-零乳腺癌中NAC的反应.
研究NAC后HER2表达的演变及其预后价值.

主要方法:

410名接受NAC治疗的HER2阴性乳腺癌患者的回顾性分析 (2017年1月至2020年12月).
评估临床病理学特征,NAC反应 (病理完整反应 - pCR) 和HER2表达演变.
在HER2-低和HER2-零组之间进行比较,包括按激素受体 (HR) 状态进行子组分析.

主要成果:

低HER2的病例显示了更高比例的HR阳性疾病 (75.8%vs65.8%).
在HER2-低和HER2-零组之间,pCR率 (ypTis/0ypN0) 没有显著差异 (33.8%对39.3%).
探索性分析显示,HER2-低患者 (ypT0ypN0定义) 的pCR率整体较低 (19.8%与33.3%) 和HR阳性小组 (12.6%与29.9%).
在NAC后的HER2表达演变发生在24.7%的HER2-低和31.0%的HER2-零患者中,在TNBC中更高的率.
HER2进化与组织学,Ki-67和淋巴结状况有关,但没有观察到预后影响.

结论:

低HER2的乳腺癌,无论是HR阳性还是HR阴性,都有不同的临床病理特征.
对NAC和HER2表达演变的治疗反应在HER2-低和HER2-零乳腺癌之间有所不同.
在HER2-低和HER2-零乳腺癌中,NAC后的HER2表达演变似乎不会影响患者的预后.

关键词:

乳腺癌乳腺癌乳腺癌 HER2-低表达的表达方式新辅助化学疗法新辅助化学疗法病理完整反应的病理完整反应.预测预测预测预测

更多相关视频

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on: October 25, 2011

相关概念视频

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...